Actinium Pharmaceuticals to Showcase Innovative Cancer Treatments at AACR Annual Meeting 2026
- Actinium Pharmaceuticals will present innovative cancer treatments ATNM-400 and Actimab-A at AACR Annual Meeting 2026.
- The presentations will emphasize the potential advancements of its Ac-225 platform in cancer therapy.
- Actinium is dedicated to improving treatment efficacy while reducing toxicity to healthy tissues.
Actinium Pharmaceuticals, Inc. is set to unveil new preclinical data for its promising radioconjugate ATNM-400 and its acute myeloid leukemia (AML) treatment, Actimab-A, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. Scheduled from April 17-22, 2026, in San Diego, California, these presentations will showcase critical findings that highlight the first-in-class efficacy of ATNM-400 across various solid tumor models. CEO Sandesh Seth emphasizes the versatility and potential of the Ac-225 platform, particularly its effectiveness against tumors that are resistant to standard therapies.
Related Cashu News
Argen X SE's Vyvgart Gains Advantage Amid Competitors' Setbacks in Biotech Market
Argen X SE (Ticker: ARGX) maintains a strong position in the biotech industry, particularly following the recent challenges faced by competitors. With Sanofi SA discontinuing its Phase 3 MOBILIZE stud…
Syndax Pharmaceuticals Advances AML Treatment with Promising SAVE Trial Results
Syndax Pharmaceuticals (Ticker: SNDX) showcases significant advancements in the treatment of acute myeloid leukemia (AML) with its recently reported Phase 1/2 SAVE trial results. The trial investigate…
Ionis Pharmaceuticals Appoints Dr. Ludwig Hantson to Enhance Strategy for RNA Therapeutics
Ionis Pharmaceuticals (Ticker: IONS) has recently appointed Ludwig Hantson, Ph.D., to its Board of Directors, marking a significant step in the company’s ongoing strategy to advance its innovative RNA…
Axsome Therapeutics Settles SUNOSI Litigation, Securing Market Exclusivity Until 2040
Axsome Therapeutics, a biopharmaceutical company focused on central nervous system (CNS) disorders, recently resolves significant litigation related to its wakefulness drug SUNOSI. This settlement per…